PD01.14 Targeting the Chemoradiation Resistance of Lung Cancers with KRAS/TP53 Co-Mutations

Recent clinical data have linked KRAS/TP53 (KP) co-mutations (mut) to resistance to radiotherapy (RT), but supporting laboratory evidence is sparse. In addition, the ability of different radiation doses, with/without EGFR-directed treatment, to achieve local tumor control as a function of KRAS status is unknown. Clonogenic radiation survival of a panel of 17 non-small cell lung carcinoma (NSCLC) cell lines was assessed. The radiosensitivity of...